L01XX - Resultats de la cerca

Unió Europea - italià - EMA (European Medicines Agency)

nexpovio

stemline therapeutics b.v. - selinexor - mieloma multiplo - agenti antineoplastici - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

lumykras 120 mg compresse rivestite con film

amgen switzerland ag - sotorasibum - compresse rivestite con film - sotorasibum 120 mg, cellulosum microcristallinum, lactosum monohydricum 114 mg, carmellosum natricum conexum corresp. natrium 1.6 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), titanii dioxidum, macrogolum 4000, talcum, e 172 (flavum), pro compresso obducto. - lumykras ist als monotherapie für die behandlung von erwachsenen patienten mit lokal fortgeschrittenem oder metastasiertem nicht-plattenepithelialem, nicht kleinzelligem lungenkarzinom (nsclc) mit kras g12c mutation indiziert, bei denen es nach einer vorherigen behandlung mit einer platinbasierten chemotherapie und/oder einer anti-pd-1/-pd-l1-immuntherapie zu einer progression gekommen ist (siehe «klinische wirksamkeit»). - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

zepzelca 4 mg polvere per concentrato per soluzione per infusione

pharmamar ag - lurbinectedinum - polvere per concentrato per soluzione per infusione - lurbinectedinum 4 mg, saccharum, acidum lacticum, natrii hydroxidum corresp. natrium 2.94 mg, pro vitro. - zepzelca ist zur behandlung von erwachsenen patienten mit metastasiertem kleinzelligem lungenkarzinom (sclc) indiziert. - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

elzonris 1mg / ml concentrato per soluzione per infusione

stemline therapeutics switzerland gmbh - tagraxofuspum - concentrato per soluzione per infusione - tagraxofuspum 1 mg, trometamolum, natrii chloridum, sorbitolum 50 mg, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile, ad solutionem pro 1 ml corresp. natrium 1.98 mg. - blastische plasmazytoide dendritische zellneoplasie (bpdcn) - biotechnologika

Unió Europea - italià - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - agenti antineoplastici - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.